📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Visiopharm

1.1 - Company Overview

Visiopharm Logo

Visiopharm

Headquarter: Denmark
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of quantitative digital pathology image analysis and stereology software, including ONCOtopix Dx; APP Center with 130+ modular tissue analysis units; machine learning-based NerValence System for biomarker testing in neurodegenerative diseases; IVDR-cleared diagnostic algorithms and an IVDR-certified PD-L1 APP integrated into lab workflows and PACS/IMS; plus OBserver remote image viewing portal.

Products and services

  • IVDR-cleared Diagnostic Algorithms: IVDR-cleared diagnostic decision support for EU and UK use, integrates directly into laboratory workflows to assist pathologists with standardized analyses
  • PD-L1 APP: IVDR-certified automated evaluation of PD-L1 in non-small cell lung cancer, integrates with pathology labs’ PACS/IMS systems for consistent staining quantification and reporting
  • APP Center: Modular platform offering over 130 analysis units tailored to specific tissue image analysis problems across diverse tissue types, stains, and modalities for targeted assay development

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Visiopharm

BioPharmics Logo

BioPharmics

HQ: United States Website
  • Description: Provider of AI-based drug design and modeling tools for researchers and scientists, offering algorithms and software for computational drug design, including 2D-to-3D ligand conversion, conformer generation, molecular docking, molecular similarity, binding affinity prediction, and real-space modeling of ligand ensembles in X-ray density maps.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full BioPharmics company profile →
uMotif Logo

uMotif

HQ: United Kingdom Website
  • Description: Provider of a scalable, engaging, patient-centred data capture platform for modern clinical research, enabling compliant, validated e-consent, eCOA, ePRO, PROM and PREM. Delivers configurable patient engagement, study-specific eDiaries on mobile and web, complex ClinROs with audio upload, telehealth for onboarding and consent, and integration with devices, sensors and third-party systems.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full uMotif company profile →
360 Vantage Logo

360 Vantage

HQ: United States Website
  • Description: Provider of cloud-based CRM, sales force automation, and closed-loop marketing systems for the life sciences industry, offering 360 CRM, 360 CLM, compliance and e-learning solutions, along with a full suite of professional and managed services.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full 360 Vantage company profile →
Within3 Logo

Within3

HQ: United States Website
  • Description: Provider of a SaaS virtual engagement and digital collaboration platform for life science companies to compliantly connect and engage physicians, nurses, payers, and patients in groups large or small; offerings include an Insights Management Platform, AI-powered virtual engagement applications for global stakeholder discussions, client success support, and data science services for disease community analysis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Within3 company profile →
Isomorphic Labs Logo

Isomorphic Labs

HQ: United Kingdom Website
  • Description: Provider of AI-driven drug discovery and development solutions, delivering machine-learning platforms that analyze biological data to identify drug candidates, help researchers understand complex biology, and predict compound effects. Engages in strategic collaborations with pharmaceutical companies and advances digital biology research, building on innovations like AlphaFold.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Isomorphic Labs company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Visiopharm

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Visiopharm

2.2 - Growth funds investing in similar companies to Visiopharm

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Visiopharm

4.2 - Public trading comparable groups for Visiopharm

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Visiopharm

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Visiopharm

What does Visiopharm do?

Visiopharm is a provider of quantitative digital pathology image analysis and stereology software, including ONCOtopix Dx; APP Center with 130+ modular tissue analysis units; machine learning-based NerValence System for biomarker testing in neurodegenerative diseases; IVDR-cleared diagnostic algorithms and an IVDR-certified PD-L1 APP integrated into lab workflows and PACS/IMS; plus OBserver remote image viewing portal.

Who are Visiopharm's competitors?

Visiopharm's competitors and similar companies include BioPharmics, uMotif, 360 Vantage, Within3, and Isomorphic Labs.

Where is Visiopharm headquartered?

Visiopharm is headquartered in Denmark.

How many employees does Visiopharm have?

Visiopharm has 1,000 employees 🔒.

When was Visiopharm founded?

Visiopharm was founded in 2010 🔒.

What sector and industry vertical is Visiopharm in?

Visiopharm is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Visiopharm

Who are the top strategic acquirers in Visiopharm's sector and industry

Top strategic M&A buyers and acquirers in Visiopharm's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Visiopharm?

Top strategic M&A buyers groups and sectors for Visiopharm include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Visiopharm's sector and industry vertical

Which are the top PE firms investing in Visiopharm's sector and industry vertical?

Top PE firms investing in Visiopharm's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Visiopharm's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Visiopharm's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Visiopharm's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Visiopharm include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Visiopharm's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Visiopharm?

The key public trading comparables and valuation benchmarks for Visiopharm include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Visiopharm for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Visiopharm with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Visiopharm's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Visiopharm with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Visiopharm's' sector and industry vertical?

Access recent funding rounds and capital raises in Visiopharm's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Visiopharm